US20120135960A2 - Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs - Google Patents
Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs Download PDFInfo
- Publication number
- US20120135960A2 US20120135960A2 US13/063,409 US200913063409A US2012135960A2 US 20120135960 A2 US20120135960 A2 US 20120135960A2 US 200913063409 A US200913063409 A US 200913063409A US 2012135960 A2 US2012135960 A2 US 2012135960A2
- Authority
- US
- United States
- Prior art keywords
- connexin
- psychotropic drug
- dose
- effect
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004089 psychotropic agent Substances 0.000 title claims abstract description 102
- 229940001470 psychoactive drug Drugs 0.000 title claims abstract description 94
- 239000003795 chemical substances by application Substances 0.000 title description 18
- 230000001225 therapeutic effect Effects 0.000 title description 13
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960003803 meclofenamic acid Drugs 0.000 claims abstract description 59
- 239000002981 blocking agent Substances 0.000 claims abstract description 32
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 17
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 14
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract description 12
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims abstract description 7
- 229960001962 mefloquine Drugs 0.000 claims abstract description 7
- DDOQBQRIEWHWBT-UHFFFAOYSA-N 2-azaniumyl-4-phosphonobutanoate Chemical compound OC(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims description 228
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 36
- 229960001058 bupropion Drugs 0.000 claims description 35
- 239000012636 effector Substances 0.000 claims description 35
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 35
- 229960002073 sertraline Drugs 0.000 claims description 34
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 31
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 31
- 229960002296 paroxetine Drugs 0.000 claims description 31
- 229960004170 clozapine Drugs 0.000 claims description 30
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 30
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 30
- 229960004341 escitalopram Drugs 0.000 claims description 29
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 29
- 229960004688 venlafaxine Drugs 0.000 claims description 29
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 25
- 229960003529 diazepam Drugs 0.000 claims description 24
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 24
- 229960001165 modafinil Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 21
- 230000002411 adverse Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 230000002295 serotoninergic effect Effects 0.000 claims description 12
- 230000002474 noradrenergic effect Effects 0.000 claims description 8
- 230000001800 adrenalinergic effect Effects 0.000 claims description 7
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 6
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 6
- 230000003371 gabaergic effect Effects 0.000 claims description 6
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 6
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 5
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 claims description 5
- 229960000836 amitriptyline Drugs 0.000 claims description 5
- 230000000742 histaminergic effect Effects 0.000 claims description 5
- 229960004644 moclobemide Drugs 0.000 claims description 5
- 229960005138 tianeptine Drugs 0.000 claims description 5
- 229960002431 trimipramine Drugs 0.000 claims description 5
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 5
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 4
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims description 4
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims description 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 4
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 4
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims description 4
- 230000002164 acetylcholinergic effect Effects 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 229960004606 clomipramine Drugs 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- 229960002866 duloxetine Drugs 0.000 claims description 4
- 229960002464 fluoxetine Drugs 0.000 claims description 4
- 229960004038 fluvoxamine Drugs 0.000 claims description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000001057 ionotropic effect Effects 0.000 claims description 4
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 230000000406 opioidergic effect Effects 0.000 claims description 4
- VZVRZTZPHOHSCK-YVLHZVERSA-N (3z)-3-(12h-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-n,n-dimethylpropan-1-amine Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=C1C1=CC=CC=C1O2 VZVRZTZPHOHSCK-YVLHZVERSA-N 0.000 claims description 3
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 claims description 3
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 claims description 3
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 claims description 3
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960002820 adrafinil Drugs 0.000 claims description 3
- CGNMLOKEMNBUAI-UHFFFAOYSA-N adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 claims description 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002495 buspirone Drugs 0.000 claims description 3
- NWPJLRSCSQHPJV-UHFFFAOYSA-N carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 claims description 3
- 229960000700 carpipramine Drugs 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 3
- 229960004278 cyamemazine Drugs 0.000 claims description 3
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004704 dihydroergotamine Drugs 0.000 claims description 3
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 3
- 229960001903 ergotamine tartrate Drugs 0.000 claims description 3
- 229960002419 flupentixol Drugs 0.000 claims description 3
- 229960002056 indoramin Drugs 0.000 claims description 3
- 229960001186 methysergide Drugs 0.000 claims description 3
- 229960000600 milnacipran Drugs 0.000 claims description 3
- 229960001785 mirtazapine Drugs 0.000 claims description 3
- 229960005254 naratriptan Drugs 0.000 claims description 3
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 3
- 229960000751 nefopam Drugs 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003544 oxetorone Drugs 0.000 claims description 3
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002776 pipamperone Drugs 0.000 claims description 3
- 229960004572 pizotifen Drugs 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 229960003708 sumatriptan Drugs 0.000 claims description 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001360 zolmitriptan Drugs 0.000 claims description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 3
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 2
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 claims description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 claims description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 2
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 2
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 claims description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 2
- 241000546188 Hypericum Species 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 2
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 claims description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 2
- UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 2
- 229960005054 acepromazine Drugs 0.000 claims description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004538 alprazolam Drugs 0.000 claims description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003036 amisulpride Drugs 0.000 claims description 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004046 apomorphine Drugs 0.000 claims description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 2
- 229960004372 aripiprazole Drugs 0.000 claims description 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000911 benserazide Drugs 0.000 claims description 2
- 229960002729 bromazepam Drugs 0.000 claims description 2
- 229960002802 bromocriptine Drugs 0.000 claims description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- 229960002574 captodiame Drugs 0.000 claims description 2
- IZLPZXSZLLELBJ-UHFFFAOYSA-N captodiame Chemical compound C1=CC(SCCCC)=CC=C1C(SCCN(C)C)C1=CC=CC=C1 IZLPZXSZLLELBJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004205 carbidopa Drugs 0.000 claims description 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 2
- 229960003120 clonazepam Drugs 0.000 claims description 2
- 229960004362 clorazepate Drugs 0.000 claims description 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims description 2
- 229960003622 clotiazepam Drugs 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 2
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims description 2
- 229960005178 doxylamine Drugs 0.000 claims description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 2
- 229960003337 entacapone Drugs 0.000 claims description 2
- 229960004943 ergotamine Drugs 0.000 claims description 2
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002336 estazolam Drugs 0.000 claims description 2
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002767 ethosuximide Drugs 0.000 claims description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003817 etifoxine Drugs 0.000 claims description 2
- IBYCYJFUEJQSMK-UHFFFAOYSA-N etifoxine Chemical compound O1C(NCC)=NC2=CC=C(Cl)C=C2C1(C)C1=CC=CC=C1 IBYCYJFUEJQSMK-UHFFFAOYSA-N 0.000 claims description 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003472 felbamate Drugs 0.000 claims description 2
- 229960004379 fentanyl hydrochloride Drugs 0.000 claims description 2
- 229960000326 flunarizine Drugs 0.000 claims description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 2
- 229960000693 fosphenytoin Drugs 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 229960003878 haloperidol Drugs 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 2
- 229960001410 hydromorphone Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 229940070023 iproniazide Drugs 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004002 levetiracetam Drugs 0.000 claims description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 2
- 210000003715 limbic system Anatomy 0.000 claims description 2
- 229960003587 lisuride Drugs 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229960003019 loprazolam Drugs 0.000 claims description 2
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 claims description 2
- 229960004391 lorazepam Drugs 0.000 claims description 2
- 229960004033 lormetazepam Drugs 0.000 claims description 2
- 229960000423 loxapine Drugs 0.000 claims description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 2
- 229940051129 meperidine hydrochloride Drugs 0.000 claims description 2
- 229960004815 meprobamate Drugs 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- 229960003955 mianserin Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- XCKKIKBIPZJUET-VYKNHSEDSA-N morphine hydrochloride Chemical compound Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XCKKIKBIPZJUET-VYKNHSEDSA-N 0.000 claims description 2
- 229960005195 morphine hydrochloride Drugs 0.000 claims description 2
- 229960000805 nalbuphine Drugs 0.000 claims description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims description 2
- RSKQGBFMNPDPLR-UHFFFAOYSA-N niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002686 niaprazine Drugs 0.000 claims description 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001454 nitrazepam Drugs 0.000 claims description 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004535 oxazepam Drugs 0.000 claims description 2
- 229960001816 oxcarbazepine Drugs 0.000 claims description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960002085 oxycodone Drugs 0.000 claims description 2
- 229960004505 penfluridol Drugs 0.000 claims description 2
- 229960004851 pergolide Drugs 0.000 claims description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 2
- 229960000482 pethidine Drugs 0.000 claims description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002695 phenobarbital Drugs 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001879 ropinirole Drugs 0.000 claims description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
- 229960003946 selegiline Drugs 0.000 claims description 2
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims description 2
- 229960003211 sulbutiamine Drugs 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 229960004724 sultopride Drugs 0.000 claims description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 2
- 229960001918 tiagabine Drugs 0.000 claims description 2
- 229960005344 tiapride Drugs 0.000 claims description 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960004603 tolcapone Drugs 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- 229960003386 triazolam Drugs 0.000 claims description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001255 viloxazine Drugs 0.000 claims description 2
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001475 zolpidem Drugs 0.000 claims description 2
- 229960000820 zopiclone Drugs 0.000 claims description 2
- 229960004141 zuclopenthixol Drugs 0.000 claims description 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000530 carbenoxolone Drugs 0.000 abstract description 6
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 abstract description 6
- 108050001175 Connexin Proteins 0.000 description 151
- 102000010970 Connexin Human genes 0.000 description 151
- 239000003112 inhibitor Substances 0.000 description 56
- 230000001430 anti-depressive effect Effects 0.000 description 49
- 238000011282 treatment Methods 0.000 description 47
- 238000010183 spectrum analysis Methods 0.000 description 41
- 239000000935 antidepressant agent Substances 0.000 description 36
- 229940005513 antidepressants Drugs 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 27
- 230000000144 pharmacologic effect Effects 0.000 description 26
- 230000002490 cerebral effect Effects 0.000 description 24
- 230000000903 blocking effect Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 238000000537 electroencephalography Methods 0.000 description 20
- 230000000506 psychotropic effect Effects 0.000 description 20
- 210000003976 gap junction Anatomy 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 230000008901 benefit Effects 0.000 description 16
- 230000002360 prefrontal effect Effects 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 15
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 210000002442 prefrontal cortex Anatomy 0.000 description 13
- 230000005062 synaptic transmission Effects 0.000 description 12
- 239000013066 combination product Substances 0.000 description 11
- 229940127555 combination product Drugs 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 239000003368 psychostimulant agent Substances 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000011287 therapeutic dose Methods 0.000 description 9
- 230000000949 anxiolytic effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000011458 pharmacological treatment Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002787 reinforcement Effects 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- VYTVPRWAGRDIIR-UHFFFAOYSA-N 2-aminoethyl diphenyl borate Chemical compound C=1C=CC=CC=1OB(OCCN)OC1=CC=CC=C1 VYTVPRWAGRDIIR-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000032140 Sleepiness Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 4
- 239000003693 atypical antipsychotic agent Substances 0.000 description 4
- 229940127236 atypical antipsychotics Drugs 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- -1 tetraalkylammonium ions Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010001488 Aggression Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 102100025623 Gap junction delta-2 protein Human genes 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 108010015417 connexin 36 Proteins 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004242 electrical synapse Anatomy 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 3
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SXRAPDIXXYFGJG-MDAHIHQXSA-N (2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybut Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 SXRAPDIXXYFGJG-MDAHIHQXSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- NWJZWHGSBTVTGM-UHFFFAOYSA-N 1-[bis(aziridin-1-yl)phosphoryl]-3-phenylurea Chemical compound C1CN1P(=O)(N1CC1)NC(=O)NC1=CC=CC=C1 NWJZWHGSBTVTGM-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 208000037870 generalized anxiety Diseases 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229960000916 niflumic acid Drugs 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960002905 tolfenamic acid Drugs 0.000 description 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- MQZOATSIFWSKKT-OASXIEIISA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 MQZOATSIFWSKKT-OASXIEIISA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical group C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000028048 Accommodation disease Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000583199 Homo sapiens Prokineticin receptor 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229940121912 Progesterone receptor agonist Drugs 0.000 description 1
- 102100030364 Prokineticin receptor 1 Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical class O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 150000008533 dibenzodiazepines Chemical class 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000010012 metabolic coupling Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 229940117394 provigil Drugs 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000007428 synaptic transmission, GABAergic Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 1
- 229950008546 trimegestone Drugs 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940018503 zyban Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01006—Catechol O-methyltransferase (2.1.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01084—D-Dopachrome decarboxylase (4.1.1.84)
Definitions
- This invention relates to improvements in therapeutic neurological and neuropsychic treatments using psychotropic molecules. More specifically, the invention enables the effects of psychotropic drugs to be modulated and/or potentiated by certain molecules, referred to here as anti-connexin agents.
- FIG. 1 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of submeningeal injection of Meclofenamic acid (MFA, black squares) or 18- ⁇ -Glycyrrhetinic acid (Beta GA, white circles).
- MFA Meclofenamic acid
- Beta GA 18- ⁇ -Glycyrrhetinic acid
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the first hour and for the second hour of recording.
- FIG. 2 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Clozapine alone (0.2 mg/kg intraperitoneally), the connexin inhibitor alone (Meclofenamic acid, 80 ng/kg per submeningeal injection), or the combination [Clozapine and connexin inhibitor].
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the Fourier transform analysis (FFT).
- FFT Fourier transform analysis
- FIG. 3 shows an analysis of the change minute-by-minute in the prefrontal cortex with an average frequency of 8 Hz by quantitative EEG of the effect of Clozapine alone (0.2 mg/kg intraperitoneally), the connexin inhibitor alone (Meclofenamic acid, 80 ng/kg per submeningeal injection) or the combination [Clozapine and connexin inhibitor].
- the x-axis shows the time in minutes and the y-axis shows the relative powers obtained in the FFT analysis.
- FIG. 4 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of the connexin inhibitor by submeningeal injection (Meclofenamic acid, 80 ng/kg), or by intraperitoneal injection (Meclofenamic acid, 2.45 mg/kg).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for 6 animals for the first hour and for the second hour of recording.
- FIG. 5 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of different doses of the connexin inhibitor by intraperitoneal injection (Meclofenamic acid, 2 mg/kg, 1 mg/kg, 0.5 mg/kg, 0.4 mg/kg).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the first hour and for the second hour of recording.
- FIG. 6 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Paroxetine (0.5 mg/kg intraperitoneally) alone, the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg by intraperitoneal injection) alone, or the combination of Paroxetine and connexin inhibitor.
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for 6 animals for the first hour and for the second hour.
- FIG. 7 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Modafinil (125 mg/kg and 250 mg/kg intraperitoneally) alone, the connexin inhibitor (Meclofenamic acid 0.4 mg/kg by intraperitoneal injection) alone, or the combination of Modafinil (125 mg/kg intraperitoneally) and connexin inhibitor.
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 8 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Diazepam (1 mg/kg intraperitoneally) alone, or the combination of Diazepam (1 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 9 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Venlafaxine (0.16 mg/kg and 4 mg/kg intraperitoneally) alone, or the combination of Venlafaxine (0.16 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 10 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Escitalopram (0.8 mg/kg and 4 mg/kg intraperitoneally) alone, or the combination of Escitalopram (0.8 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 11 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Bupropion (0.16 mg/kg, 0.8 mg/kg and 4 mg/kg intraperitoneally) alone, or the combination of Bupropion (0.16 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 12 shows the spectral analysis of the electrical activity of the prefrontal cortex by quantitative EEG of the effect of Sertraline (0.16 mg/kg, 0.8 mg/kg and 4 mg/kg intraperitoneally) alone, or the combination of Sertraline (0.16 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- the x-axis shows the frequencies analyzed and the y-axis shows the relative powers obtained from the FFT analysis.
- the spectral analysis is shown as an average for the 6 animals for the first hour and for the second hour.
- FIG. 13 shows a diagrammatic representation of the EEG effect in the form of an inverted “U” for sertraline alone according to the dose administered over the two recording hours (0.16 mg/kg, 0.8 mg/kg and 4 mg/kg intraperitoneally) alone, or the combination of Sertraline (0.16 mg/kg intraperitoneally) with the connexin inhibitor (Meclofenamic acid, 0.4 mg/kg intraperitoneally).
- gap junctions connect the cell cytoplasm, enabling the exchange of ions (Ca + and K + ), second messengers (AMPc, GMPc, IP3), several small metabolites (glucose) and ensuring electrical and metabolic coupling between the cells.
- the gap junctions are junctions with a selective permeability, formed by protein channels contained in the plasma membrane, and formed by connexin hexamers (Meda P, Médecine/Sciences 1996; 12: 909-920).
- Connexins are integral proteins of the plasma membrane, which are synthesized by practically every cell type, regardless of the position of a multicellular organism in the phylogenesis of the animal world. In vertebrates, occasional cells not producing connexins are adult striated muscle cells, spermatozoids and circulating blood cells. Unlike numerous membrane proteins, connexins have a short half-life (between 3 and 6 hours), are not glycosylated and do not have an enzymatic activity. At present, at least thirteen distinct connexins have been identified in mammals; corresponding, in humans, to 21 isoforms.
- connexin In practice, various types of connexin can be present in a plurality of tissues, and most of the cells synthesize a plurality of connexins (Meda P, Médecine/Sciences 1996; 12: 909-920). Before reaching the cell membrane, the connexins assembly in groups of six molecules to form hollow tubular structures called connexons, which join the plasma membrane by means of Golgi vesicles. When cell contact is established, the connexons of a cell align end-to-end with those of the neighboring cell, establishing a continuous hydrophilic channel around 10 nm long. This junctional channel establishes direct contact between the cytoplasms of the two cells in contact, over the intercellular space.
- connexin 36 connexin 36
- Mice deficient in connexin 36 do not have any inter-neuron coupling, which helps to confirm the leading role of these particular connexins in at least one type of electrical synapse (Wellershaus K, Exp Cell Res. 2008).
- the electrical synapses do not transmit information faster than chemical synapses, but have a particular characteristic, that of reciprocity: neither inhibiting nor excitatory, they locally synchronize the state of multiple cells, and bilaterally.
- the gap junctions acting as low pass filters, this process of normalization of the state of the cells is more effective as it involves more or less long-term changes. Electrical couplings between neurons, owing to their characteristics, would play a role in oscillation phenomena and rhythmic discharges in the neocortex and the hippocampus.
- connexins are present everywhere in the different brain structures and are involved locally in the oscillations of electrical activities.
- connexins also play an important role in the general regulation of the electrical activity of the brain. Surprisingly, when they are physiologically present, these proteins indeed have a general desynchronizing role on the electrical activity of the CNS, damping and potentially neutralizing burst phenomena. Conversely, the inhibition of these molecules by means of so-called “anti-connexin” agents makes it possible to synchronize and therefore increase the electrophysiological activity measured.
- this invention proposes a method for evaluating the effective psychotropic drug equivalent dose that may be combined with the connexin blocking agent in the treatment of a patient suffering from psychiatric and/or neurodegenerative disorders. This combination is intended to obtain the same therapeutic effect as that of the psychotropic drug alone administered at a stronger dose, but with fewer adverse effects.
- the “effective equivalent dose” of a psychotropic drug refers to the psychotropic drug dose that, when administered in combination with the connexin blocking agent, induces a physiological effect or a pharmacological signature similar or identical to that of the psychotropic drug alone administered at the active pharmacological dose.
- the “pharmacologically active dose” of a psychotropic drug refers to the psychotropic drug dose classically administered to laboratory animals such as rats, mice, rabbits and so on. Such doses are provided, for example, in Animal models in psychopharmacology . Olivier B, S GmbH J, Mos J, eds. Birkhauser Verlag, Basel; 1991. If this dose is not known, it is possible to determine the pharmacologically active dose of the psychotropic drug by transposing, in the animal, the pharmacologically active doses classically prescribed in humans and that can be consulted in “Médicaments psychotropes: Why etrise en France modiapolitaine. I.
- the pharmacologically active dose is the maximum psychotropic drug dose that can be administered to an animal without the adverse effects becoming more pronounced than the therapeutic effect.
- the pharmacologically active dose can be determined cumulatively by administering a plurality of psychotropic drug doses at increasing doses and by measuring, each time, the effect produced by said drug.
- a “connexin-blocking” agent is a chemical molecule, a protein, a protein fragment or a nucleic acid (RNAi) capable of inhibiting the functional activity of connexins, directly and/or indirectly, and more generally any type of intercellular junctions, and/or capable of functionally inhibiting, directly and/or indirectly any cellular activity involving a connexin-type protein.
- RNAi nucleic acid
- Such an agent can also be referred to as an “anti-connexin molecule”.
- the method for evaluating the effective equivalent dose of a psychotropic drug is based on the quantification of the potentiation of the effect of the psychotropic drug by the agent blocking the connexins.
- This evaluation is performed in several steps: a step of characterization of the effects specific to the psychotropic agent and a step of measuring the dose benefit of the combination product.
- the first step consists of determining and quantifying the effects of the psychotropic drug alone at different doses (pharmacologically active dose and doses decreasing from the pharmacologically active dose), and thus having signatures specific to the psychotropic molecule—or standard signatures—at the different doses.
- the second step consists of determining the psychotropic drug dose, which, administered in combination with the connexin-blocking agent, has the same pharmacological signature as the psychotropic drug alone.
- the dose of connexin-blocking agent used in combination with the psychotropic drug is first determined by experimental tests.
- This dose indeed corresponds to the maximum dose of connexin-blocking agent that can be administered without producing a significant specific pharmacological effect.
- This dose can be adjusted when implementing the method according to the invention so as to optimize the effect of the combination.
- the effective equivalent dose of the psychotropic drug i.e. the dose of psychotropic drug that, when administered in combination with the connexin-blocking agent, produces the same effect as that of the psychotropic drug alone administered at said pharmacologically active dose.
- This method for evaluating the effective equivalent dose of a psychotropic drug also makes it possible to evaluate the dose benefit between a combination product combining said psychotropic drug at the effective equivalent dose and a connexin-blocking agent and the psychotropic drug administered at the pharmacologically active dose.
- dose benefit refers, in this application, to the ratio between the pharmacological dose of the psychotropic drug alone and the effective equivalent dose of the psychotropic drug.
- dose benefit explains by how much the pharmacological dose of a prescribed psychotropic drug can be reduced in view of its combination with the anti-connexin agent. This reduction in the psychotropic drug dose administered (in combination with the anti-connexin molecules) will not have any consequence in terms of efficacy of the treatment, but will reduce adverse effects.
- BD Pharmacologically ⁇ ⁇ active ⁇ ⁇ dose ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ psychotropic ⁇ ⁇ drug Effective ⁇ ⁇ equivalent ⁇ ⁇ dose ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ psychotropic ⁇ ⁇ drug
- said animal groups are of the same species. Moreover, each animal group receives exclusively either a dose of psychotropic drug alone, or a combination product containing a certain dose of psychotropic drug and an anti-connexin agent, so as to measure, in the animals of the same group, only the effect of said drug or of said combination product alone.
- said animal groups are the same age and same sex. These animals are preferably laboratory animals, for example rats, mice, rabbits and so on.
- the number of doses to be tested is determined according to the pharmacological effect of the psychotropic drug or of the combination product combining the psychotropic drug and the connexin-blocking agent; when the pharmacological effect produced by a certain dose is non-existent or insignificant, it is no longer necessary to use lower doses.
- the administration of the drug or of the combination product can be performed intracerebrally, but is preferably performed intraperitoneally.
- the effect produced by the psychotropic drug and/or the combination product can be determined by different types of analysis, in particular an electrophysiological or behavioral analysis or blood markers or LCR markers, or by medical imaging.
- this effect is determined by reference to an electrophysiological response resulting from a given stimulation, in particular in reference to the electroencephalographic activity (EEG) of the animal.
- EEG electroencephalographic activity
- This evaluation method also makes it possible to make a selection with regard to the nature of the connexin-blocking agent, to the psychotropic drug, as well as to the doses used.
- this invention relates to a new combination product containing at least one connexin-blocking agent and a psychotropic drug, and the use thereof in patients with psychiatric and/or neurodegenerative disorders.
- the family of fenamates includes the following compounds: meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. These compounds all have a non-steroidal anti-inflammatory activity, but this activity is not responsible for their capacity to block the gap junctions. It has indeed been suggested that the fenamates instead establish a direct interaction with the connexins or with the protein membrane interfaces that may influence the conformation of the connexins and therefore the functional role thereof (Harks E G, The Journal of Pharmacology and Experimental Therapeutics 2001 September, 298 (3): 1033-41).
- Benzoic 2-[(2,6-di-chloro-3-phenyl)amino] acid is a non-steroidal anti-inflammatory agent and a peripheral analgesic of the fenamate class, a prostaglandin inhibitor, described among the water-soluble blockers as being the most effective for reversibly blocking the gap junctions.
- meclofenamic acid is not specific to a type of connexin and is therefore effective for blocking a large number of cerebral connexins (Pan F, Vis Neurosciences 2007, July-August; 24 (4): 609-18).
- Glycyrrhetinic acid derivatives refer to 18- ⁇ -glycyrrhetinic acid (BGA) also known as “enoxolone”, 18- ⁇ -glycyrrhetinic acid and carbenoxolone acid, which are triterpinoid saponins known for inhibiting the 11-hydroxysteroid dehydrogenase enzyme. Moreover, these compounds are capable of very effectively inhibiting the gap junctions (Pan F, Vis Neurosciences 2007, July-August; 24 (4): 609-18).
- Mefloquine of the quinine family, also has a strong antagonist power on the gap junctions (Srinivas M, PNAS 2001, 98: 10942-10947; Pan F, Vis Neurosciences 2007, July-August; 24 (4):609-18).
- Some anesthetic agents such as halothane and isoflurane, have a rapid and reversible gap junction blocking effect (Burt J M, et al, Circ Research. 1989; 65: 829-37).
- oleamide(cis-9-octadecenamide), the first amide of oleic acid also has an inhibiting action on the connexin molecules 43 and 32 (Guan X. et al, J. Cell Biol 1997; 139: 1785-92).
- cyclodextrins ( ⁇ -cyclodextrin ( ⁇ -CD), ⁇ -cyclodextrin ( ⁇ -CD) and ⁇ -cyclodextrin ( ⁇ -CD)), which are natural cyclical oligosaccharides of ⁇ -D-glucopyranose, have proven anti-connexin properties (Locke D. et al, J. Biol Chem 2004; 279: 22883-92).
- 2-aminoethyldiphenyl borate (2-APB) is a compound recently identified as a gap junction-blocking agent (Bai D, J Pharmacol Exp Ther, 2006 December; 319 (3): 1452-8).
- This modulator of the inositol 1,4,5-triphosphate receptor however fairly specifically targets certain connexins, such as connexins 26, 30, 36, 40, 45 and 50 (Bai D, J Pharmacol Exp Ther, 2006 December; 319 (3): 1452-8).
- the peptides corresponding to the extracellular sequences include the conserved patterns QPG and SHVR of E1 (Gap26) and the conserved pattern SRPTEK of E2 (Gap27) of the connexins are more effective for blocking the gap junctions (Chaytor A T et al, J. Physiol 1997; 503: 99-110).
- the connexin-blocking agents are advantageously chosen from: long-chain alcohols (for example, heptanol and octanol), fenamates (for example, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid), arylaminobenzoates, aminosulfonates (for example taurine), glycyrrhetinic acid derivatives (for example, 18- ⁇ -glycyrrhetinic acid, 18- ⁇ -glycyrrhetinic acid and carbenoxolone), oleamides (for example, cis-9-octadecenamide), or tetraalkylammonium ions and polyamines (such as spermine and spermidine), quinine derivatives (such as mefloquine), 2-ABP, anesthetic agents (halothane or isoflurane), cyclod
- the connexin-blocking agent is included in the group including melofenamic acid, 18- ⁇ -glycyrrhetinic acid, carbenoxolone, mefloquine and 2-APB, and more preferably in the group including meclofenamic acid, 18- ⁇ -glycyrrhetinic acid and carbenoxolone.
- Some molecules with a recognized anti-connexin function have also been described for their anti-inflammatory effect, their anesthetic effect or their effect on prostaglandin homeostasis, and therefore, by themselves have effects on the central nervous system.
- the activities other than anti-connexin activities are not involved in these effects.
- the use of low doses allows for better tissue specificity depending on the connexin composition of the tissue, because the CNS is especially rich in connexin.
- the anti-inflammatory molecules can indirectly produce, by their action on the prostaglandin synthase, a structural modification of the connexins (the regulation of the connexin expression levels or of the phosphorylation thereof occurs in particular via PI3K and PKA, themselves dependent on the activity levels of Cox, NO and PG synthetase, targets of anti-inflammatories).
- This modification in the sense of a reduction in the presence of the connexins in the junctions, indirectly causes a reduction in the functional activity of the connexins similar to a direct blocking of the connexins.
- the formation of functional gap junctions can be regulated by means of connexin phosphorylation.
- phosphorylation of certain protein domains of the hexamer sub-units leads to an inhibition in the functionality of the gap junctions, according to the phosphorylation site, by closing the channels or by reducing the presence at the membrane (modification of traffic and half-life of sub-units) (Scemes E, Glia 2008 Jan. 15, 56 (2): 145-53; Postma F R, J Cell Biol 1998 Mar. 9, 140 (5): 1199-209; Shaw R M, Cell 2007, Feb. 9, 128 (3): 547-60; Fabrizi G M, Brain 2007 February, 130 (Pt2): 394-403).
- molecules can have an indirect gap junction-blocking effect, via the phosphorylation levels of the connexins. They are in particular: lysophosphatidic acid, thrombin and neuropeptides, such as endothelin (Postma F R, J Cell Biol 1998 Mar. 9, 140 (5): 1199-209).
- the connexin-blocking agent has an indirect effect on the connexins and the gap junctions, and it is chosen from the group consisting of: lysophosphatidic acid, thrombin and neuropeptides, such as endothelin.
- the connexin-blocking agent is neither an anesthetic agent nor an anti-inflammatory agent, nor a prostaglandin synthesis inhibitor.
- the connexin-blocking agent is 2-amino ethoxy diphenyl borate (2-APB).
- the connexin-blocking agent can advantageously improve the therapeutic effect of psychotropic drugs prescribed by a physician for treating a patient suffering from a psychiatric and/or neurodegenerative disorder. In animals, this improvement can be measured by the method for evaluating the effective equivalent dose, which is the first objective of the invention.
- Psychotropic agent refers to any substance that acts primarily on the state of the central nervous system by modifying certain cerebral biochemical and physiological processes.
- This invention differs from the prior art in that, in the combination product, therapeutic benefits produced by the connexin-blocking agent are not specific to the use of a psychotropic drug in particular, but apply similarly to numerous molecules having psychotropic effects.
- the psychotropic drugs are chosen from the dopaminergic, GABAergic, adrenergic, acetylcholinergic, serotoninergic, opioidergic, adenosinergic, ionotropic, histaminergic, IMAO, Catechol-O-methyl transferase, DOPA decarboxylase and noradrenergic psychotropic effectors.
- effector refers to any substance activating or inhibiting one or more neuroreceptors, and can therefore be an agonist or an antagonist of said receptors.
- the psychotropic drug is a dopaminergic effector such as loxapine, acepromazine, methylphenidate, amantadine, pergolide, lisuride, bromocriptine, ropinirole, apomorphine, aripiprazole, sulpiride, amisulpride, sultopride, tiapride, pimozide, lisperidone, haloperidol, penfluridol, zuclopenthixol or bupropion.
- a dopaminergic effector such as loxapine, acepromazine, methylphenidate, amantadine, pergolide, lisuride, bromocriptine, ropinirole, apomorphine, aripiprazole, sulpiride, amis
- the psychotropic drug is a GABAergic effector such as tiagabine, topiramate, clorazepate, diazepam, clonazepam, oxazepam, lorazepam, bromazepam, lormetazepam, nitrazepam, clotiazepam, alprozolam, estazolam, triazolam, loprazolam, etifoxin, meprobamate, zopiclone, zolpidem, phenobarbital, felbamate or vigabatrine.
- GABAergic effector such as tiagabine, topiramate, clorazepate, diazepam, clonazepam, oxazepam, lorazepam, bromazepam, lormetazepam, nitrazepam, clotiazepam, alprozolam, estazolam
- the psychotropic drug is an adrenergic effector such as dihydroergotamine, modafinil, adrafinil, mirtazapine and oxetorone.
- the psychotropic drug is an acetylcholinergic effector such as sulbutiamine, tropatepin or trihexyphenidyl.
- the psychotropic drug is a serotoninergic effector such as chlorpromazine, trimipramine, clozapine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, amitriptyline, duloxetine, venlafaxine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline, tianeptine, milnacipran, amitriptyline, trimipramine, viloxazine, tianeptine, hypericum and lithium.
- a serotoninergic effector such as chlorpromazine, trimipramine
- the psychotropic drug is an opioidergic effector such as nalbuphine, buprenorphine, pethidine, codeine, tramadol, morphine, hydromorphone, oxycodone, methadone, dextropropoxyphene, meperidine, fentanyl, naltrexone or morphine hydrochloride.
- opioidergic effector such as nalbuphine, buprenorphine, pethidine, codeine, tramadol, morphine, hydromorphone, oxycodone, methadone, dextropropoxyphene, meperidine, fentanyl, naltrexone or morphine hydrochloride.
- the psychotropic drug is an adenosinergic effector such as carbamazepine or oxcarbazepine.
- the psychotropic drug is an ionotropic effector such as flunarizine, ethosuximide, levetiracetam, lamotrigine, fosphenytoin or phenyloin.
- the psychotropic drug is a histaminergic effector such as niaprazine, hydroxyzine or doxylamine.
- the psychotropic drug is a monoamine oxidase effector such as moclobemide, selegiline or iproniazid.
- the psychotropic drug is a catechol-O-methyl transferase effector such as entacapone or tolcapone.
- the psychotropic drug is a DOPA decarboxylase effector such as benserazide or carbidopa.
- the psychotropic drug is a noradrenergic effector such as mianserine, desipramine, moclobemide or bupropion.
- the psychotropic drug is an effector acting on the limbic system, such as gabapentin or captodiamine.
- the psychotropic molecule chosen is clozapine, a dibenzodiazepine derivative, or paroxetine, escitalopram, sertraline or venlafaxine, which are serotoninergic effectors or any other serotoninergic effector such as chlorpromazine, trimipramine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, fluoxetine, citalopram, amitriptyline, duloxetine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline or tianeptine.
- serotoninergic effectors or any other serotoninergic effector such as chlorpromazine, trimipramine, olanzapine
- the psychotropic molecule chosen is modafinil, a diphenylmethane derivative, which is an adrenergic effector or any other adrenergic psychotropic effector such as dihydroergotamine, adrafinil, mirtazapine or oxetorone.
- the psychotropic molecule is chosen from: modafinil, clozapine, paroxetine, diazepam, venlafaxine, escitalopram, bupropion or sertraline.
- the psychotropic molecule is an antidepressant chosen from: moclobemide (MOCLAMINE), amitriptyline (LAROXYL), clomipramine (ANAFRANIL), milnacipran (IXEL), escitalopram (SEROPLEX), citalopram (SEROPRAM), fluoxetine (PROZAC), paroxetine (DEROXAT), fluvoxamine (FLOXYFRAL), sertraline (ZOLOFT), mitrapazine (NORSET), duloxetine (Cymbalta) or venlafaxine (EFFEXOR) and bupropion (ZYBAN).
- MOCLAMINE moclobemide
- LAROXYL amitriptyline
- ANAFRANIL milnacipran
- IXEL escitalopram
- SEROPRAM citalopram
- fluoxetine PROZAC
- paroxetine DEOXAT
- fluvoxamine FLOXYFRAL
- sertraline Z
- the psychotropic molecule is an antidepressant chosen from the group including: paroxetine, venlafaxine, escitalopram, bupropion and sertraline.
- this invention also relates to the use of this product in combination, simultaneously, separately or sequentially, in patients with psychiatric and/or neurodegenerative disorders.
- Patients needing this treatment may have psychiatric and/or neurodegenerative disorders included in the group consisting of: depression, bipolar disorder, epilepsy, schizophrenia, generalized anxiety, depression, conditions due to stress, panic, phobias, obsessive compulsive disorders, behavioral disorders, immune system depression, fatigue and symptoms associated with pain, chronic fatigue, fibromyalgia, and other disorders such as autism, attention deficit, hyperactivity, eating disorders such as bulimia, anorexia, obesity, psychic disorders such as apathy, migraine, pain, cardiovascular diseases, neurodegenerative disorders and disorders associated with depressive anxiety (Alzheimer's disease, Huntington's disease, Parkinson's disease), drug dependence and drug addiction.
- psychiatric and/or neurodegenerative disorders included in the group consisting of: depression, bipolar disorder, epilepsy, schizophrenia, generalized anxiety, depression, conditions due to stress, panic, phobias, obsessive compulsive disorders, behavioral disorders, immune system depression, fatigue and symptoms associated with pain, chronic fatigue,
- the two components of the treatment are administered to the patient simultaneously.
- the two components can be packaged together, in the form of a mixture, or separately, then mixed spontaneously before being administered together to the patient. More commonly, the two components are administered simultaneously, but separately.
- the routes of administration of the two components may be different.
- the administration can also be performed at different sites.
- the two components are administered sequentially or spaced apart over time, for example in the same day or at an interval ranging from several hours to several weeks, or even several months.
- this invention involves the use of at least one connexin-blocking agent for preparing a drug intended to be administered before, at the same time, or after a psychotropic drug, in order to treat a patient suffering from psychiatric and/or neurodegenerative disorders.
- the invention includes the use of at least one connexin-blocking agent, for modulating and/or potentiating the effect of a psychotropic drug in patients with psychiatric and/or neurodegenerative disorders.
- modulate in this case means intervening, by potentiation or antagonism, on the direct or indirect effects of the psychotropic drug administered before, simultaneously or after the anti-connexin agent, in particular on the adverse effects.
- the term “potentiate” in this case means significantly increasing the effects of the psychotropic drug administered before, simultaneously or after the anti-connexin agent.
- the combination of the psychotropic drug with the anti-connexin agent makes it possible to reduce the doses of said psychotropic drug and therefore to limit the adverse effects of said psychotropic drug, and/or to reduce the effects of failure and withdrawal.
- the invention therefore also relates to the use of at least one connexin-blocking agent, for reducing the doses of said psychotropic drug and/or limiting the adverse effects of said psychotropic drug, and/or reducing the effects of failure and withdrawal.
- the invention describes a method for treating a patient with psychiatric and/or neurodegenerative disorders, including the administration to said patient of:
- Electroencephalography is the measurement of the electrical activity of the brain by means of electrodes placed on the scalp, often represented in the form of a line called the electroencephalogram. Comparable to the electrocardiogram, which makes it possible to study the functioning of the heart, the EEG is a painless and noninvasive examination that provides information on the neurophysiologic activity of the brain over time and in particular of the cerebral cortex, either for a diagnostic neurological purpose or for cognitive neuroscience research purposes.
- the electric signal at the basis of the EEG is the resultant, for each frequency, of the summation of the synchronous post-synaptic action potentials produced by a large number of neurons.
- the electrical power associated with each frequency can vary independently of that of the others as a function of the individual's behavior or the drug administered (Dimpfel W, Neuropsychobiology. 1986: 15 (2): 101-8).
- the electroencephalogram of the patient changes, and the distribution of the potentials associated with each frequency constitutes the electropharmacogram of said drug.
- the electropharmacograms are different for drugs prescribed for different diseases, and are similar when they are intended to treat the same pathologies (Dimpfel W, British Journal of Pharmacology, 2007, 152, 538-548).
- Electrophalmacograms corresponding to more than 150 drugs have been determined (for example, analgesics, antidepressants, neuroleptics, stimulants, tranquilizers, sedatives and narcotics).
- analgesics for example, analgesics, antidepressants, neuroleptics, stimulants, tranquilizers, sedatives and narcotics.
- the parameters of the EEG make it possible to obtain quantitative information on the development in the clinical phase of numerous compounds (Mandema & Danhof, Clin. Pharmacokinet. 1992, 23, 191-215).
- the measurement of the EEG potential can also be used to identify the cell receptors of the drugs administered (Parker T J, British Journal of Pharmacology 2001, 132, 151-158).
- the EEG is a measurement of the electrical activity of the brain and there are different modes for representing electroencephalographic data.
- the first is the representation of the lines and the identification of characteristic undulation phenomena. This qualitative data is informative for clearly determined episodes of electrical activity, but does not provide information on the quantitative aspect of the electrical activity.
- the experimenter uses the quantitative EEG based on the analysis of the Fourier transform signal making it possible to obtain power values for a given frequency over time.
- This power value is associated with a control value that makes it possible to determine the power modification for a given frequency over time. This value may be averaged by time periods variable according to the experiments.
- the EEG potential is very high for very low frequencies (between 0.8 and 4.5 Hz) (delta rhythm) and between 7 and 9.5 Hz (alpha rhythm I), and low intensity at frequencies between 4.75 and 6.75 Hz (theta rhythm) and greater than 18.5 Hz (beta rhythm), which is the sign of a positive clinical response (Galderisi S, Methods Find Exp Clin Pharmacol, 2002, 24, 85-89).
- the EEG potential is at average intensity on frequencies ranging from 8 to 15 Hz, which can involve extrapyramidal side effects.
- an EEG potential of average intensity in the second hour for frequencies of 7-9.5 Hz and 12.75-18.50 Hz means that adverse effects will be present (Dimpfel W, British Journal of Pharmacology 2007, 152, 538-548).
- a group of 6 conscious Wistar rats was pre-implanted with 6 bipolar bilateral electrodes (2 frontal, 2 anterior hippocampic, 2 posterior hippocampic).
- meclofenamic acid (Sigma) is performed by slow submeningeal injection (80 mg/kg, 4.5 pg/second) or intraperitoneally at different doses.
- the injection of glycyrrhetinic acid (Sigma) is performed by submeningeal injection (80 mg/kg).
- the injection of clozapine (Sigma) is performed intraperitoneally (0.2 mg/kg).
- the injection of paroxetine (Sigma) is performed intraperitoneally (0.5 mg/kg).
- modafinil (Cephalon) is performed intrapelitoneally (125 mg/kg and 250 mg/kg).
- the EEG measurements were performed on the different groups of conscious rats (previously implanted and habituated) by 2-hour recordings after injection.
- the spectral analysis performed by Fourier transform (FFT) makes it possible to obtain relative powers, Hertz-by-Hertz and second-by-second.
- the FFT data is then averaged minute-by-minute and associated with the solvent control produced the day prior to the recording under strictly identical experimental conditions.
- the relative spectral powers of the left and right prefrontal cortices are then averaged by 5-minute periods, averaged by groups of 12 5-minute repetitions and represented hour-by-hour.
- the significance threshold of the relative power modifications for a given frequency for a psychotropic drug alone with respect to the control (solvent of the psychotropic agent) or a psychotropic drug in combination with an anti-connexin with respect to the psychotropic agent administered alone (in favor of a relative power increase or a decrease) was chosen at a value of P ⁇ 0.05.
- Clozapine is an atypical antipsychotic indicated for schizophrenia, a serotoninergic and dopaminergic receptor antagonist, alternatively an adrenergic, cholinergic and histaminergic antagonist having a typical complex EEG activation spectrum (Parker T J, British Journal of Pharmacology 2001, 132, 151-158) and a considerable list of adverse effects at therapeutic doses (weight gain, decrease in bone marrow and number of leukocytes in the blood).
- the spectral analysis of the EEGs shows a significant increase in the EEG potential, and therefore in the synchronization of the prefrontal cerebral activity (200%) for frequencies of 8-10 Hz and to a lesser extent for frequencies of 16-20 Hz during the treatment with the antipsychotic alone, from the first hour and extending to the second hour ( FIG. 2 ).
- the spectral analysis of the EEGs shows a significant increase in the synchronization of the prefrontal cerebral activity (260%) for frequencies of 8-10 Hz and to a lesser extent for frequencies of 16-20 Hz at the first hour.
- This significant increase in synchronization corresponds to the clozapine spectrum and therefore corresponds to a potentiation of the effect of clozapine by blocking of the connexin junction system.
- This mechanism of reinforcement of the effect of clozapine by the anti-connexin is controlled over time. Indeed, at the second hour, only the anti-connexin effect persists ( FIG. 2 ).
- the damping of the fluctuations caused by clocking of the connexin junction system means that the connexins may play a role in the establishment of these brief fluctuations in electrophysiological activity. These fluctuations would correspond to quick activity kindling mechanisms produced the clozapine and controlled by the connexins.
- the spectral analysis of the EEGs shows a significant increase comparable to the synchronization of the prefrontal cerebral activity at the first hour and for similar frequency ranges. However, the significant increase in synchronization continues at the second hour for peripheral administration, whereas it decreases for central administration. This difference at the second hour is associated with the pharmacokinetics of the administration routes ( FIG. 4 ).
- These important synchronizations according to the dose may be due to the quantitative representation (number of variable gap junctions according to the central nervous system network, ex: cholinergic, noradrenergic, serotoninergic, etc.) and/or qualitative representation (affinity of the different connexin isoforms for the inhibitor at the given dose) of connexins.
- Paroxetine is an antidepressant, indicated for acute or chronic depressive episodes, derived from phenylpiperidine of the selective serotonin reuptake inhibitor group and having a considerable list of adverse effects at the therapeutic doses (apathy, pupil dilation, nausea, teratogenicity, somnolence, headaches, weight and appetite changes, changes in sexual behavior, increase in feelings of depression and anxiety, dry mouth, aggressive behavior (in particular in children), possible congenital deformations, erythema, psychomotor instability, itching, depletion (sodium), sweating, suicidal ideation, muscle weakness, muscle pain, unusual levels of aggression, serotonin syndrome).
- MFA meclofenamic acid
- the spectral analysis of the EEGs shows a significant increase in the relative powers in the prefrontal cortex, and therefore in the synchronization of the prefrontal cerebral activity (around 200%) at 8-10 Hz and to a lesser extent for frequencies of 2-3 Hz and 18-19 Hz in the treatment with the antidepressant alone, at the first hour and increasing (around 300%) at the second hour for frequencies of 8-10 Hz and to a lesser extent for frequencies of 2-3 Hz and 18-19 Hz ( FIG. 6 ).
- the spectral analysis of the EEGs shows a significant increase in the synchronization of the prefrontal cerebral activity (600%) for frequencies of 8-10 Hz and to a lesser extent for frequencies of 2-3 Hz and 18-19 Hz at the second hour.
- This significant increase in synchronization corresponds perfectly to the spectrum for paroxetine alone and therefore corresponds to a considerable potentiation of the effect of paroxetine by blocking the connexin junction system.
- this mechanism of reinforcement of the effect of paroxetine by the anti-connexin follows the same time course as the paroxetine alone. Indeed, paroxetine alone or in combination with the anti-connexin causes EEG effects that increase at the second hour and that must wear off several hours after administration ( FIG. 6 ).
- paroxetine produces effects that are more prolonged over time and that take more time to develop.
- the potentiation by the anti-connexin therefore retains the time course properties of the psychotropic molecules studied (of different chemical natures, targeting different systems and with very different indications) and reinforces the notion of a system of modulation by connexins that is not limited to a single neurotransmission system.
- Modafinil is a psychostimulant, indicated for the treatment of narcolepsy and idiopathic hypersomnia, a noradrenaline reuptake inhibitor with a list of adverse effects at therapeutic doses (excitation, aggressiveness, insomnia, anorexia, headaches, nausea, stomach ache, allergic skin eruptions).
- the experimental model was evaluated with the published data providing in particular the pharmacological doses of modafinil in an acute treatment, which are generally 100 to 350 mg/kg (Sebban C, British Journal of Pharmacology (1999) 128, 1045-1054, De saint Hilaire Z., Neuroreport. 2001 Nov. 16; 12 (16): 3533-7). Recordings of the effect of modafinil alone at two doses (125 and 250 mg/kg) were therefore produced.
- the spectral analysis of the EEGs shows a significant increase in the EEG potential, and therefore in the synchronization of the prefrontal cerebral activity (300% the 250 mg/kg dose and 120% for the 125 mg/kg dose) for frequencies of 2-5 Hz and a significant decrease in the EEG potential, and therefore a desynchronization in the prefrontal cerebral activity (10 to 30%) for frequencies of 10-25 Hz for the 125 mg/kg dose and to a lesser extent for the 250 mg/kg dose for the treatment with the psychostimulant alone, at the first hour and increasing at the second hour ( FIG. 7 ).
- Diazepam is an anxiolytic, indicated for excessive anxiety episodes, sleeping difficulties, neurotic states, psychosomatic manifestations, alcohol detoxification and epilepsy. Diazepam is a benzodiazepine facilitating GABAergic transmission, with a considerable list of adverse effects at therapeutic doses (somnolence, hypotonia, feeling of intoxication, difficulty concentrating, irritability, aggressiveness, excitation, confusion, hepatitis, allergic skin reactions, dysphagia) and can lead to tolerance and dependence requiring a dosage adjustment during the various phases of the treatment.
- MFA meclofenamic acid
- the experimental model was evaluated in order to compare it with the bibliographic data on the EEG effect of diazepam administered intraperitoneally in the conscious rat (Robledo P., Alcohol Clin Exp Res. 1994 April; 18 (2)-363-8). Recordings of the effect of diazepam alone were therefore produced at the 1 mg/kg dose administered intraperitoneally (1.5 to 5 times less than the dose normally used in an acute treatment in the rat).
- the spectral analysis of the EEGs shows, at the first hour, the characteristic effects of diazepam, namely a slight decrease in power of the 4-7 Hz components (around 25% decrease) and a significant increase in the power of the 11-30 Hz components (around 120%). At the second hour, these effects on the 4-7 Hz and the 11-30 Hz components persist while reducing in intensity and a significant increase in the power of the 1-3 Hz components appears (cf. FIG. 8 ).
- the spectral analysis of the EEGs shows, at the first hour, a significant increase in the power for the 11-30 Hz components (around 150%) and the 1-3 Hz components (around 120%). This increase in power continues at the second hour with a higher amplitude for the 11-30 Hz components (up to 200%) (cf. FIG. 8 ).
- this potentiation of the GABAergic system confirms the hypothesis of a modulating role (likely qualitatively and quantitatively dependent on the organization in the chemical neurotransmission systems) on the electrophysiological activities by the connexin junction system.
- Venlafaxine is an antidepressant, indicated for major depressive episodes in adults, the prevention of recurrent depression in patients with a unipolar disorder, and generalized anxiety for at least 6 months in adults.
- Venlafaxine is a serotonin and noradrenaline reuptake inhibitor, with an intermediate profile, and with an efficacy comparable to that of the imipramines, and has a considerable list of adverse effects at therapeutic doses (nausea, somnolence, dry mouth, insomnia, vertigo, constipation, sweating, hyponatremia, difficulty ejaculating, diarrhea, vomiting, weight gain, headaches, agitation, shaking, paresthesia, palpitations, accommodation disorder, skin eruptions) and can cause a withdrawal syndrome when the treatment is stopped.
- venlafaxine In a first phase, the experimental model was evaluated with venlafaxine alone, because no bibliographic data on the EEG effect of venlafaxine in the conscious rat IS available; however, various studies on the effects of venlafaxine, in particular on sleep modifications, provide the pharmacological doses of venlafaxine in acute treatment, which are generally from 1 to 10 mg/kg administered intraperitoneally (Salin-Pascual R J., Psychopharmacology. 1997 February; 129 (3): 295-6).
- the spectral analysis of the prefrontal EEGs shows a significant increase in power, according to the venlafaxine dose, of the 8-10 Hz components (around 120% for the 0.16 mg/kg dose and 200% for the 4 mg/kg dose) and 16-18 Hz components and to a lesser extent the 24-26 Hz components at the first hour and increasing at the second hour with the appearance of an increase in the power of 1-3 Hz components at 4 mg/kg ( FIG. 9 ).
- the spectral analysis of the EEGs shows, at the first hour, a significant increase in the power for the 8-10 Hz components (around 350%), 16-18 Hz components (around 200%) and 24-26 Hz components (around 180%).
- This increase in power continues at the second hour with a decrease in amplitude for the different components (primarily for the 8-10 Hz components) except for the 1-3 Hz components, for which a significant increase in power is observed (cf. FIG. 9 ).
- Escitalopram is an antidepressant, indicated for major depressive states and the prevention of panic attacks with or without agoraphobia.
- Escitalopram is a serotonin reuptake inhibitor, with an intermediate profile, and with an efficacy comparable to that of the imipramines, and has a considerable list of adverse effects at therapeutic doses (nausea, headaches, insomnia, constipation, somnolence, sweating, difficulty ejaculating, diarrhea, vomiting, vertigo, trembling, paresthesia, palpitations, orthostatic hypotension and pruritis).
- the spectral analysis of the prefrontal EEGs shows a significant increase in power, according to the escitalopram dose, of the 6-8 Hz components (around 150% for the 0.8 mg/kg dose and 200% for the 4 mg/kg dose) and 14-16 Hz components and to a lesser extent the 22-24 Hz components at the first hour and decreasing at the second hour (cf. FIG. 10 ).
- the spectral analysis of the EEGs shows, at the first hour, a significant increase in the power for the 6-8 Hz components (around 450%), 14-16 Hz components (around 230%) and 22-24 Hz components (around 14%). This increase in power continues at the second hour with a decrease in amplitude for the different components (primarily for the 8-10 Hz components) (cf. FIG. 10 ).
- bupropion in combination with a connexin inhibitor, meclofenamic acid (MFA) were studied.
- MFA meclofenamic acid
- Bupropion is an antidepressant, indicated to help in smoking cessation in nicotine-dependent subjects.
- Bupropion is a noradrenaline and dopamine reuptake inhibitor, with a considerable list of adverse effects at therapeutic doses (skin eruption, pruritis, fever, nausea, headaches, insomnia, vertigo, constipation, vomiting, ataxia, tinnitus, mental confusion, visual disturbances).
- the experimental model was evaluated because no bibliographic data on the EEG effect of bupropion in the conscious rat is available; however, various studies on the effects of bupropion, in particular on sleep EEG modifications, provide the pharmacological doses of bupropion in acute treatment, which are generally from 5 to 150 mg/kg administered intraperitoneally (Henshall D C, Neuropsychiatr Dis Trat. 2009; 5: 189-206).
- the spectral analysis of the prefrontal EEGs shows a significant increase in power, according to the bupropion dose, of the 8-10 Hz components from 8-10 Hz (around 180% for the 0.16 mg/kg dose, 450% for the 0.8 mg/kg dose and 280% for the 4 mg/kg dose) and 15-18 Hz components and to a lesser extent the 23-25 Hz components at the first hour.
- a significant increase with respect to the first hour is observed for the same components for the doses 0.16 mg/kg and 4 mg/kg, while the effect wears off at the 0.8 mg/kg dose ( FIG. 11 ).
- the spectral analysis of the EEGs shows, at the first hour, a significant increase in the power for the 8-10 Hz components (around 400%), components 15-18 Hz (around 230%) and 23-25 Hz components (around 140%). This increase in power continues at the second hour with a decrease in amplitude for the different components primarily for the 8-10 Hz and 15-18 Hz components) (cf. FIG. 11 ).
- Sertraline is an antidepressant, indicated for major depressive states in adults, obsessive compulsive disorders in adults and children, and the prevention of recurrent depression in patients with a unipolar disorder.
- Sertraline is a selective serotonin reuptake inhibitor, with a considerable list of adverse effects at therapeutic doses (skin rashes, pruritis, nausea, headaches, insomnia, vertigo, vomiting, extrapyramidal effect, difficulty ejaculating, constipation, visual disturbances, tachycardia).
- the spectral analysis of the prefrontal EEGs shows a significant increase in power, according to the sertraline dose, of the 7-9 Hz components (around 260% for the 0.16 mg/kg dose and the 0.8 mg/kg dose and 200% for the 4 mg/kg dose) and 14-17 Hz components and to a lesser extent the 23-25 Hz components at the first hour.
- a significant increase with respect to the first hour is observed for the same components for the 0.8 mg/kg (900%) and 4 mg/kg (450%) doses, while the effect wears off slightly at the 0.16 mg/kg dose ( FIG. 12 ).
- the spectral analysis of the EEGs shows, at the first hour, a significant increase in power for the 7-9 Hz components (around 400%), 14-17 Hz components (around 300%) and 23-25 Hz components (around 160%). This increase in power continues at the second hour with a considerable increase in amplitude for the different components, primarily for the 7-9 Hz components (around 1000%) and 14-17 Hz components (around 700%) ( FIG. 12 ).
- this potentiation of the serotoninergic system confirms the hypothesis of a modulating role on the electrophysiological activities by the connexin junction system.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0856090 | 2008-09-10 | ||
FR0856090A FR2935611B1 (fr) | 2008-09-10 | 2008-09-10 | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
PCT/EP2009/061765 WO2010029131A1 (fr) | 2008-09-10 | 2009-09-10 | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/061765 A-371-Of-International WO2010029131A1 (fr) | 2008-09-10 | 2009-09-10 | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/736,004 Division US11077080B2 (en) | 2008-09-10 | 2015-06-10 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110172188A1 US20110172188A1 (en) | 2011-07-14 |
US20120135960A2 true US20120135960A2 (en) | 2012-05-31 |
Family
ID=40552073
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/063,409 Abandoned US20120135960A2 (en) | 2008-09-10 | 2009-09-10 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
US14/736,004 Active US11077080B2 (en) | 2008-09-10 | 2015-06-10 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/736,004 Active US11077080B2 (en) | 2008-09-10 | 2015-06-10 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
Country Status (12)
Country | Link |
---|---|
US (2) | US20120135960A2 (fr) |
EP (1) | EP2344146B1 (fr) |
JP (2) | JP5809976B2 (fr) |
CN (2) | CN107519157A (fr) |
AU (1) | AU2009290861B2 (fr) |
CA (1) | CA2736623C (fr) |
DK (1) | DK2344146T3 (fr) |
ES (1) | ES2420120T3 (fr) |
FR (1) | FR2935611B1 (fr) |
HK (1) | HK1160015A1 (fr) |
IL (1) | IL211694A (fr) |
WO (1) | WO2010029131A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190351008A1 (en) * | 2016-06-13 | 2019-11-21 | Uti Limited Partnership | Methods and compositions for modulating opioid withdrawal symptoms |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2586436A1 (fr) | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Utilisation d'agents anti-connexine pour améliorer l'effet thérapeutique d'un inhibiteur de l'acétylcholinestérase |
WO2013179264A2 (fr) | 2012-05-30 | 2013-12-05 | Universidad Andres Bello | Utilisation de composés qui modulent sélectivement la libération astrocytaire de substances par les hémicanaux de connexine et de pannexine, sans influencer les jonctions communicantes, pour le traitement des troubles psychiatriques |
PL3024458T3 (pl) * | 2013-07-24 | 2018-08-31 | Commissariat à l'énergie atomique et aux énergies alternatives | Zastosowanie flekainidu jako środka anty-koneksynowego oraz sposób wzmacniania efektów działania leku psychotropowego |
EP3041577B1 (fr) * | 2013-09-06 | 2021-07-21 | Knut M. Wittkowski | Traitement et prévention de l'autisme et des troubles du spectre autistique |
JP2016535006A (ja) * | 2013-10-15 | 2016-11-10 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 白血病細胞の根絶のための方法および組成物 |
JP6898848B2 (ja) | 2014-09-19 | 2021-07-07 | メモリアル スローン ケタリング キャンサー センター | 脳転移を治療するための方法 |
US20160317477A1 (en) | 2015-04-30 | 2016-11-03 | Ovid Therapeutics Inc. | Methods of treating prader-willi syndrome |
CA2992162A1 (fr) * | 2015-07-15 | 2017-01-19 | Theranexus | Utilisation de l'amitriptyline pour le blocage des connexons du cerveau et procede d'amplification de son effet in vivo |
US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
JP6694289B2 (ja) * | 2016-02-12 | 2020-05-13 | 株式会社日立製作所 | 薬効評価補助システム、及び薬効評価補助情報提示方法 |
JP2019517469A (ja) | 2016-05-26 | 2019-06-24 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. | ピプラドロールを用いる行動症候群の治療方法 |
EP3481387A4 (fr) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | Methodes et compositions pour le traitement de troubles épileptiques |
KR20200107927A (ko) | 2017-09-28 | 2020-09-16 | 아스데라 엘엘씨 | 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도 |
EP3593822A1 (fr) | 2018-07-13 | 2020-01-15 | Theranexus | Applications thérapeutiques et diagnostiques d'un nouveau procédé de surveillance d'une interaction neurogliale (memri) |
FR3110393B1 (fr) | 2020-05-20 | 2022-05-06 | Grn Consulting | Compose et composition pour induire une neuroprotection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002139A2 (fr) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection de cellules ganglionnaires de la retine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107349A1 (en) * | 2003-07-24 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
EP1516625A1 (fr) * | 2003-09-16 | 2005-03-23 | Institut Pasteur | Utilisation des pannexines formant des canaux neuronaux dans la thérapie et la diagnose chez les mammifères |
WO2005046667A2 (fr) * | 2003-11-07 | 2005-05-26 | Research Foundation For Mental Hygiene, Inc. | Inhibiteurs du transport par le systeme a permettant de traiter ou de prevenir des troubles neuropsychiatriques |
CA2556380A1 (fr) * | 2004-03-02 | 2005-09-15 | Pharmacia Corporation | Procedes et compositions pour le traitement ou la prevention de troubles psychiatriques avec des inhibiteurs de cox-2 seuls et en combinaison avec des antidepresseurs |
JP2009516751A (ja) * | 2005-11-21 | 2009-04-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ | 神経保護のための小分子化合物を使用する方法 |
CN101062039B (zh) * | 2006-04-30 | 2010-05-12 | 北京华安佛医药研究中心有限公司 | 治疗神经系统疾病的药物组合物 |
US20100015105A1 (en) * | 2006-12-27 | 2010-01-21 | Shimon Marom | Method of treating schizophrenia |
US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
-
2008
- 2008-09-10 FR FR0856090A patent/FR2935611B1/fr not_active Expired - Fee Related
-
2009
- 2009-09-10 ES ES09782881T patent/ES2420120T3/es active Active
- 2009-09-10 JP JP2011526492A patent/JP5809976B2/ja not_active Expired - Fee Related
- 2009-09-10 US US13/063,409 patent/US20120135960A2/en not_active Abandoned
- 2009-09-10 AU AU2009290861A patent/AU2009290861B2/en not_active Ceased
- 2009-09-10 CN CN201710570051.1A patent/CN107519157A/zh active Pending
- 2009-09-10 DK DK09782881.8T patent/DK2344146T3/da active
- 2009-09-10 CN CN200980138043.3A patent/CN102164594B/zh not_active Expired - Fee Related
- 2009-09-10 WO PCT/EP2009/061765 patent/WO2010029131A1/fr active Application Filing
- 2009-09-10 CA CA2736623A patent/CA2736623C/fr not_active Expired - Fee Related
- 2009-09-10 EP EP09782881.8A patent/EP2344146B1/fr not_active Not-in-force
-
2011
- 2011-03-10 IL IL211694A patent/IL211694A/en active IP Right Grant
-
2012
- 2012-01-18 HK HK12100586.6A patent/HK1160015A1/xx not_active IP Right Cessation
-
2015
- 2015-05-28 JP JP2015108133A patent/JP2015172067A/ja not_active Withdrawn
- 2015-06-10 US US14/736,004 patent/US11077080B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002139A2 (fr) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection de cellules ganglionnaires de la retine |
Non-Patent Citations (2)
Title |
---|
Turner et al. (Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biological psychiatry 55.10 (2004): 1031-1040) * |
Urbano et al. (Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci U S A. Jul 24, 2007; 104(30): 12554-12559 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017285725B2 (en) * | 2016-06-13 | 2021-08-19 | Uti Limited Partnership | Methods and compositions for modulating opioid withdrawal symptoms |
US20190351008A1 (en) * | 2016-06-13 | 2019-11-21 | Uti Limited Partnership | Methods and compositions for modulating opioid withdrawal symptoms |
US11298569B2 (en) * | 2016-06-13 | 2022-04-12 | Uti Limited Partnership | Methods and compositions for modulating opioid withdrawal symptoms |
US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11865126B2 (en) | 2019-04-17 | 2024-01-09 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Also Published As
Publication number | Publication date |
---|---|
EP2344146A1 (fr) | 2011-07-20 |
EP2344146B1 (fr) | 2013-04-17 |
CN107519157A (zh) | 2017-12-29 |
US20110172188A1 (en) | 2011-07-14 |
FR2935611A1 (fr) | 2010-03-12 |
CN102164594A (zh) | 2011-08-24 |
DK2344146T3 (da) | 2013-07-08 |
AU2009290861A1 (en) | 2010-03-18 |
CA2736623A1 (fr) | 2010-03-18 |
WO2010029131A1 (fr) | 2010-03-18 |
CN102164594B (zh) | 2021-09-28 |
WO2010029131A9 (fr) | 2010-06-10 |
HK1160015A1 (en) | 2012-08-10 |
ES2420120T3 (es) | 2013-08-22 |
IL211694A0 (en) | 2011-06-30 |
JP5809976B2 (ja) | 2015-11-11 |
JP2012502082A (ja) | 2012-01-26 |
US11077080B2 (en) | 2021-08-03 |
AU2009290861B2 (en) | 2015-08-06 |
IL211694A (en) | 2015-05-31 |
FR2935611B1 (fr) | 2010-10-15 |
JP2015172067A (ja) | 2015-10-01 |
CA2736623C (fr) | 2018-05-15 |
US20150272915A1 (en) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11077080B2 (en) | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs | |
Ziemann | TMS and drugs | |
Miyamoto | Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders | |
Addolorato et al. | Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation | |
Reilly et al. | Pharmacological treatment effects on eye movement control | |
Somers et al. | Transcutaneous electrical nerve stimulation for the management of neuropathic pain: the effects of frequency and electrode position on prevention of allodynia in a rat model of complex regional pain syndrome type II | |
Müller et al. | The in vivo neurochemistry of the brain during general anesthesia | |
Schwartz et al. | Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy | |
Termine et al. | Emerging treatment strategies in Tourette syndrome: what’s in the pipeline? | |
Ahnaou et al. | Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep–wake architecture | |
John et al. | Caffeine promotes glutamate and histamine release in the posterior hypothalamus | |
CN107949379A (zh) | L‑4‑氯代犬尿氨酸的治疗用途 | |
Bhattacharya et al. | NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate | |
Ramage et al. | NMDA receptor expression and activity in osteoarthritic human articular chondrocytes | |
Marcus et al. | Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens | |
Schaffler et al. | Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse®) with its single active ingredients diclofenac and orphenadrine: A Placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin | |
Fisher et al. | Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat | |
Sun et al. | Altered glutamate metabolism contributes to antiepileptogenic effects in the progression from focal seizure to generalized seizure by low-frequency stimulation in the ventral hippocampus | |
Turgeon et al. | The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm | |
US20090143450A1 (en) | Method for treating central pain syndrom or for inducing centrally generated pain in an animal model | |
Cairns et al. | Intramuscular ketorolac inhibits activation of rat peripheral NMDA receptors | |
Wohlfarth et al. | Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation | |
Onat et al. | Experimental absence versus amygdaloid kindling | |
Zarindast et al. | Morphine-induced place preference: interactions with neurotransmitter systems | |
van Balken et al. | Current and future therapeutic approaches in progressive supranuclear palsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOUTHON, FRANCK;CHARVERIAT, MATHIEU;DESLYS, JEAN-PHILIPPE;AND OTHERS;SIGNING DATES FROM 20110316 TO 20110318;REEL/FRAME:026245/0963 Owner name: BIO MODELING SYSTEMS OU BMSYSTEMS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOUTHON, FRANCK;CHARVERIAT, MATHIEU;DESLYS, JEAN-PHILIPPE;AND OTHERS;SIGNING DATES FROM 20110316 TO 20110318;REEL/FRAME:026245/0963 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |